Literature DB >> 1708224

Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli.

L J Piddock1, R N Walters, J M Diver.   

Abstract

The effects of nalidixic acid and four fluoroquinolones on DNA, RNA, and protein synthesis in the presence and absence of 20 mg of chloramphenicol per liter were examined by comparing the killing kinetics, MIC, morphological response, and maximum concentration to induce recA in Escherichia coli. All agents demonstrated paradoxical killing kinetics, in that above an optimum concentration the rate of bactericidal action was slower. Filamentation of E. coli AB1157 was observed with all quinolones up to the optimum bactericidal concentration. Addition of chloramphenicol reduced the bactericidal activity, inhibited filamentation, and abolished recA induction, but it had no effect on DNA synthesis inhibition by any of the agents. Excellent correlation was obtained between the concentration required to inhibit DNA synthesis by 50%, the MIC, the maximum concentration to induce recA, and the optimum bactericidal concentration. Evidence from this study and previously published data suggest that the primary mechanism of action of quinolones is independent of the SOS response and does not require active protein synthesis; however, induction of recA and SOS responses is consequential and enhances cell death.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1708224      PMCID: PMC172056          DOI: 10.1128/AAC.34.12.2331

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Nalidixic acid and bacterial chromosome replication.

Authors:  G C Crumplin; J T Smith
Journal:  Nature       Date:  1976-04-15       Impact factor: 49.962

2.  Survival of recombination-deficient mutants of Escherichia coli during incubation with nalidixic acid.

Authors:  L S McDaniel; L H Rogers; W E Hill
Journal:  J Bacteriol       Date:  1978-06       Impact factor: 3.490

3.  Genetic control of DNA initiation in Escherichia coli.

Authors:  W H Schubach; J D Whitmer; C I Davern
Journal:  J Mol Biol       Date:  1973-02-25       Impact factor: 5.469

4.  Synthesis of ribonucleic acid and protein in plasmid-containing minicells of Escherichia coli K-12.

Authors:  K J Roozen; R G Fenwick; R Curtiss
Journal:  J Bacteriol       Date:  1971-07       Impact factor: 3.490

5.  The requirement for potassium for bacteriophage T4 protein and deoxyribonucleic acid synthesis.

Authors:  P S Cohen; H L Ennis
Journal:  Virology       Date:  1965-11       Impact factor: 3.616

6.  Model for regulation of Escherichia coli DNA repair functions.

Authors:  L J Gudas; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

7.  Mechanism of action of nalidixic acid on Escherichia coli. 3. Conditions required for lethality.

Authors:  W H Deitz; T M Cook; W A Goss
Journal:  J Bacteriol       Date:  1966-02       Impact factor: 3.490

8.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

9.  Nalidixic Acid and the Metabolism of Escherichia coli.

Authors:  E B Winshell; H S Rosenkranz
Journal:  J Bacteriol       Date:  1970-12       Impact factor: 3.490

10.  Alteration of bacterial DNA structure, gene expression, and plasmid encoded antibiotic resistance following exposure to enoxacin.

Authors:  J B Courtright; D A Turowski; S A Sonstein
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

View more
  26 in total

1.  Flow cytometric investigation of filamentation, membrane patency, and membrane potential in Escherichia coli following ciprofloxacin exposure.

Authors:  H J Wickens; R J Pinney; D J Mason; V A Gant
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Medium plays a role in determining expression of acrB, marA, and soxS in Escherichia coli.

Authors:  Andrew M Bailey; Mark A Webber; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

Review 3.  Quinolone-mediated bacterial death.

Authors:  Karl Drlica; Muhammad Malik; Robert J Kerns; Xilin Zhao
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

4.  Impact of DNA gyrase inhibition by antisense ribozymes on rec A in E. coli.

Authors:  Sainath Rao Shilpakala; Malathi Raghunathan
Journal:  Mol Biol Rep       Date:  2008-11-04       Impact factor: 2.316

5.  Hydroxyl radicals are involved in cell killing by the bacterial topoisomerase I cleavage complex.

Authors:  I-Fen Liu; Thirunavukkarasu Annamalai; Jeanette H Sutherland; Yuk-Ching Tse-Dinh
Journal:  J Bacteriol       Date:  2009-06-12       Impact factor: 3.490

6.  Gene expression changes triggered by exposure of Haemophilus influenzae to novobiocin or ciprofloxacin: combined transcription and translation analysis.

Authors:  H Gmuender; K Kuratli; C P Gray; W Keck; S Evers
Journal:  Genome Res       Date:  2001-01       Impact factor: 9.043

7.  Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.

Authors:  L J Piddock; M Zhu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 8.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

Review 9.  Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

Review 10.  Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.

Authors:  Charles W Stratton
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.